Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma

BACKGROUND AND PURPOSE: Drug repurposing represents a promising approach to safely accelerate the clinical application of therapeutics with anti‐cancer activity. In this study, we examined whether inhibition of the anti‐apoptotic Bcl‐2 family proteins Bcl‐2 and Bcl‐xL enhances the biological effects...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Pharmacol
Main Authors: Halatsch, Marc‐Eric, Kast, Richard Eric, Dwucet, Annika, Hlavac, Michal, Heiland, Tim, Westhoff, Mike‐Andrew, Debatin, Klaus‐Michael, Wirtz, Christian Rainer, Siegelin, Markus David, Karpel‐Massler, Georg
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6715605/
https://ncbi.nlm.nih.gov/pubmed/31222722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14773
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares